← All trials
NCT06927986
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 30, 2025
- Primary completion
- Jul 30, 2026
- Completion date
- Aug 30, 2026
- First posted
- Apr 15, 2025
- Last posted
- Nov 17, 2025
- Enrollment
- 380
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shijiazhuang Pharma Group (CSPC)Lead sponsor
- Chinese Academy of Medical SciencesOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.